STOK Quote, Financials, Valuation and Earnings

Krystal Biotech, Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of 47.99%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Krystal Biotech, Inc.'s return on equity of 19.22%.

Stoke Therapeutics, Inc. has a consensus price target of $41.70, signalling upside risk potential of 14.53%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $313.22 which suggests that it could grow by 13.64%. Given that Stoke Therapeutics, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Stoke Therapeutics, Inc. is more attractive than Krystal Biotech, Inc..

Stoke Therapeutics, Inc. has a beta of 1.071, which suggesting that the stock is 7.082% more volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.486, suggesting its less volatile than the S&P 500 by 51.361%.

Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are smaller than Krystal Biotech, Inc. quarterly revenues of $107.1M. Stoke Therapeutics, Inc.'s net income of -$38.3M is lower than Krystal Biotech, Inc.'s net income of $51.4M. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 55.18x while Krystal Biotech, Inc.'s PE ratio is 40.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 10.33x versus 21.20x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of -121.83%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Moderna, Inc.'s return on equity of -29.19%.

Stoke Therapeutics, Inc. has a consensus price target of $41.70, signalling upside risk potential of 14.53%. On the other hand Moderna, Inc. has an analysts' consensus of $42.25 which suggests that it could fall by -21.13%. Given that Stoke Therapeutics, Inc. has higher upside potential than Moderna, Inc., analysts believe Stoke Therapeutics, Inc. is more attractive than Moderna, Inc..

Stoke Therapeutics, Inc. has a beta of 1.071, which suggesting that the stock is 7.082% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.291, suggesting its more volatile than the S&P 500 by 29.087%.

Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are smaller than Moderna, Inc. quarterly revenues of $678M. Stoke Therapeutics, Inc.'s net income of -$38.3M is higher than Moderna, Inc.'s net income of -$826M. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 55.18x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 10.33x versus 10.72x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Scholar Rock Holding Corp. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of --. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Scholar Rock Holding Corp.'s return on equity of -142.69%.

Stoke Therapeutics, Inc. has a consensus price target of $41.70, signalling upside risk potential of 14.53%. On the other hand Scholar Rock Holding Corp. has an analysts' consensus of $50.36 which suggests that it could grow by 13.75%. Given that Stoke Therapeutics, Inc. has higher upside potential than Scholar Rock Holding Corp., analysts believe Stoke Therapeutics, Inc. is more attractive than Scholar Rock Holding Corp..

Stoke Therapeutics, Inc. has a beta of 1.071, which suggesting that the stock is 7.082% more volatile than S&P 500. In comparison Scholar Rock Holding Corp. has a beta of 0.697, suggesting its less volatile than the S&P 500 by 30.329%.

Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Scholar Rock Holding Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Scholar Rock Holding Corp. pays out -- of its earnings as a dividend.

Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are larger than Scholar Rock Holding Corp. quarterly revenues of --. Stoke Therapeutics, Inc.'s net income of -$38.3M is higher than Scholar Rock Holding Corp.'s net income of -$102.2M. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 55.18x while Scholar Rock Holding Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 10.33x versus 72.82x for Scholar Rock Holding Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Zymeworks, Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of -70.99%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Zymeworks, Inc.'s return on equity of -18.82%.

Stoke Therapeutics, Inc. has a consensus price target of $41.70, signalling upside risk potential of 14.53%. On the other hand Zymeworks, Inc. has an analysts' consensus of $36.46 which suggests that it could grow by 56.56%. Given that Zymeworks, Inc. has higher upside potential than Stoke Therapeutics, Inc., analysts believe Zymeworks, Inc. is more attractive than Stoke Therapeutics, Inc..

Stoke Therapeutics, Inc. has a beta of 1.071, which suggesting that the stock is 7.082% more volatile than S&P 500. In comparison Zymeworks, Inc. has a beta of 1.229, suggesting its more volatile than the S&P 500 by 22.853%.

Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zymeworks, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Zymeworks, Inc. pays out -- of its earnings as a dividend.

Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are smaller than Zymeworks, Inc. quarterly revenues of $27.6M. Stoke Therapeutics, Inc.'s net income of -$38.3M is lower than Zymeworks, Inc.'s net income of -$19.6M. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 55.18x while Zymeworks, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 10.33x versus 13.12x for Zymeworks, Inc.. Usually stocks with elevated PS ratios are considered overvalued.